Safety and Clinical Efficacy of S12024 in Patients with Mild to Moderate Alzheimer’s Disease

Autor:	Hervé Allain, Eric Neuman, David Guez, Muriel Malbezin, Jean Lepagnol, Florence Mahieux
Rok vydání:	1997
Předmět:	medicine.medical_specialty Recall business.industry Internal medicine medicine In patient Clinical efficacy Disease Core symptoms business Selection (genetic algorithm)
Zdroj:	Alzheimer Disease ISBN: 9781461286608
DOI:	10.1007/978-1-4612-4116-4_45
Popis:	The selection of S12024 as a candidate for the treatment of core symptoms of Alzheimer’s disease (AD) was based upon the central noradrenergic and/or vasopressinergic implication hypothesis of AD (Palmer et al., 1987, Van Ree et al., 1985) and the pharmacological data in mnestic models animals in two areas of memory, i.e. acquisition and recall (Lacroix et al., 1993: Raaijmakers et al., 1994: Carey et al., 1993).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ed492cb100f43e1f84a0a1bab42c5189 https://doi.org/10.1007/978-1-4612-4116-4_45 Zobrazit plný text záznamu